SCHEMBL29720453

SCHEMBL29720453

Cn1ccc(-c2nc(O)c3scc(-c4ccccn4)c3n2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.44
CYP19A1 P11511 2/20 0.37
PDE10A Q9Y233 1/20 0.37
KRAS P01116 1/20 0.37
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
BRD4 O60885 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
BAZ2B Q9UIF8 1/20 0.35
BAZ2A Q9UIF9 1/20 0.35
NPC1 O15118 3/20 0.35
LMNA P02545 3/20 0.35
RAB9A P51151 3/20 0.35
HPGD P15428 2/20 0.35
CASP3 P42574 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24128044 1.00 PRKCI (0.44) PRKCICYP19A1PDE10AKRASKDM4E
SCHEMBL20665754 0.86 KDM4E (0.49) CYP19A1PDE10AKDM4ETDP1NPC1
SCHEMBL29720641 0.81 PRKCI (0.42) PRKCICYP19A1PDE10AKRASKDM4E
SCHEMBL24128147 0.81 PRKCI (0.42) PRKCICYP19A1PDE10AKRASKDM4E
SCHEMBL24827580 0.79 PDE10A (0.45) CYP19A1PDE10AKRASKDM4ETDP1
SCHEMBL24128157 0.79 KDM4E (0.41) PRKCICYP19A1PDE10AKDM4ETDP1
SCHEMBL29720643 0.79 KDM4E (0.41) PRKCICYP19A1PDE10AKDM4ETDP1
SCHEMBL20665472 0.78 PDE10A (0.36) PRKCICYP19A1PDE10AKRASKDM4E
SCHEMBL20665609 0.78 KDM4E (0.42) CYP19A1PDE10AKRASKDM4ETDP1
SCHEMBL18997517 0.78 RAB9A (0.53) PRKCICYP19A1PDE10AKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168414-A1 SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE Shy Therapeutics LLC (US) 2023-04-26 EP disclosed
WO-2021257828-A9 SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2022-07-21 WO disclosed